{
    "clinical_study": {
        "@rank": "116190", 
        "brief_summary": {
            "textblock": "To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related\n      Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with\n      AIDS-related Kaposi's sarcoma.\n\n      IL-4 exhibits a variety of beneficial effects on the immune system and is a potent inhibitor\n      of Kaposi's sarcoma cells in vitro."
        }, 
        "brief_title": "A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma", 
        "completion_date": {
            "#text": "April 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "IL-4 exhibits a variety of beneficial effects on the immune system and is a potent inhibitor\n      of Kaposi's sarcoma cells in vitro.\n\n      Patients are stratified into two groups according to CD4 count (less than 100 cells/mm3 and\n      greater than or equal to 100 cells/mm3) and are enrolled in cohorts of four patients at each\n      of four dose levels of IL-4 per stratum. Within each stratum, if patients at a given dose\n      level have received at least 2 weeks of study therapy and no more than two patients\n      experienced grade 3 or 4 drug-related toxicity, dose escalation in subsequent patients may\n      begin. The MTD is defined as the dose at which 50 percent of patients develop grade 3 or\n      worse toxicity.  Patients with CD4 count less than 500 cells/mm3 (per 12/30/94 amendment)\n      must be on antiretroviral therapy during study treatment.\n\n      PER AMENDMENT 11/20/95: Group I - enrollment is closed, the objective has been defined.\n      Group II - patients must have CD4 cells greater than or equal to 100/mm3 and less than\n      500/mm3.\n\n      PER AMENDMENT 11/20/95: All patients will receive antiretroviral therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Antiretroviral therapy during study treatment only in patients with CD4 count < 500\n             cells/mm3 (per 12/30/94 amendment).\n\n        Allowed:\n\n          -  G-CSF for a second occurrence of grade 3 or 4 neutropenia (per 12/30/94 amendment).\n\n          -  Nonsteroidal anti-inflammatory agents including acetaminophen for drug-related\n             fevers.\n\n          -  Systemic steroids for no more than 1 week in any 30-day period.\n\n          -  PCP prophylaxis with TMP/SMX, dapsone, or inhaled pentamidine, if patient has a\n             history of PCP or a CD4 count < 250 cells/mm3.\n\n        Allowed only in patients with CD4 count < 100 cells/mm3:\n\n          -  Maintenance doses of ganciclovir, pyrimethamine/sulfa and TMP/SMX for stable,\n             well-controlled opportunistic infections.\n\n          -  Non-myelosuppressive treatment IND medications.\n\n        Prior Medication: Required: PER AMENDMENT 11/20/95:\n\n          -  Stable dose of antiretroviral therapy required for at least 21 days prior to study\n             entry for all patients. (Changed from -  Stable dose of antiretroviral therapy for at\n             least 21 days prior to study entry in patients with CD4 count < 500 cells/mm3 (per\n             12/30/94 amendment).\n\n        Patients must have:\n\n          -  AIDS-related Kaposi's sarcoma.\n\n          -  PER AMENDMENT 11/20/95: CD4 lymphocyte count >= 100 but < 500 cells/mm3. (Changed\n             from -  HIV infection.)\n\n          -  PER AMENDMENT 11/20/95: All Patients will receive antiretroviral therapy. (Changed\n             from - Current antiretroviral therapy IF CD4 count < 500 cells/mm3 (per 12/30/94\n             amendment).)\n\n          -  No active opportunistic infections requiring induction therapy.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Other active malignancies (except basal cell carcinoma of the skin and in situ\n             cervical cancer).\n\n          -  Alteration in mental status that may prevent compliance.\n\n          -  Cardiac functional capacity of Class II or worse OR regional wall abnormalities or\n             abnormal ejection fraction on two-dimensional echocardiogram, if performed.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Chemotherapy, interferons, or immune modulators for Kaposi's sarcoma.\n\n          -  Myelosuppressive agents such as induction doses of ganciclovir, Fansidar\n             (pyrimethamine/sulfadoxine), or any other investigational drugs (with the exception\n             of non-myelosuppressive treatment IND medications in specific patients).\n\n          -  GM-CSF or erythropoietin (except for a second grade 3/4 neutropenia or anemia).\n\n          -  G-CSF.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of myocardial infarction or significant arrhythmias.\n\n          -  History of symptomatic hypoglycemia.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Systemic therapy (including chemotherapy, interferons, and immune modulators) for\n             Kaposi's sarcoma within 4 weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "48", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000769", 
            "org_study_id": "ACTG 224", 
            "secondary_id": "11201"
        }, 
        "intervention": {
            "intervention_name": "Interleukin-4", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Interleukin-4"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Interleukin-4"
        ], 
        "lastchanged_date": "April 27, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA CARE Center CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Med. Ctr., ACTG CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma", 
        "overall_official": [
            {
                "last_name": "Miles S", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Scadden D", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Miles SA, Mitsuyasu R, LaFleur F, Ryback M, Kasden P, Suckow C, Groopman J, Scadden D. Phase I/II trial of interleukin-4 in KS (ACTG 224). Int Conf AIDS. 1994 Aug 7-12;10(1):46 (abstract no 159B)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000769"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess Med. Ctr., ACTG CRS": "42.358 -71.06", 
        "Massachusetts General Hospital ACTG CRS": "42.358 -71.06", 
        "UCLA CARE Center CRS": "34.052 -118.244"
    }
}